{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-26-000043","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2026-05-13T10:30:53+00:00","discovered_at":"2026-05-13T10:35:00.327323+00:00","generated_at":"2026-05-13T10:36:40.137366+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Q1 net income $91.2M on warrant gain; cash $466M; FDA grants COMP360 rolling NDA submission","bullets":["FDA granted Compass NDA rolling submission for COMP360 in TRD based on positive Phase 3 data; CNPV awarded.","Net income $91.2M ($0.71 basic EPS) vs net loss $17.9M in Q1 2025; non-cash warrant gain of $130.9M.","Cash $466.0M at Mar 31 2026 (from $149.6M at Dec 31 2025); debt $50.5M (from $31.6M).","R&D expenses $26.5M (down from $30.9M); G&A $16.4M (down from $18.7M).","Final NDA submission on track for Q4 2026; 26-week COMP006 data expected early Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-26-000043","json":"https://secwatch.observer/filing/0001816590-26-000043.json","markdown":"https://secwatch.observer/filing/0001816590-26-000043.md","text":"https://secwatch.observer/filing/0001816590-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/0001816590-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/cmps-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T10:36:40.137366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"377537210f5fa6fc5e30b7a43a59d76a1fce2e22","claim":"COMPASS Pathways plc reported for the three months ended March 31, 2026 results: net income $91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted), EPS $0.71 net income per share (basic) and $0.30 net loss per share (diluted). Guidance reaffirmed.","evidence_excerpt":"Compass Pathways plc (the “Company”) issued a press release announcing the Company's financial results for the three months ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000043/0001816590-26-000043-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the three months ended March 31, 2026"},{"label":"Net income","value":"$91.2 million, or $0.71 net income per share (basic) and $0.30 net loss per share (diluted)"},{"label":"EPS","value":"$0.71 net income per share (basic) and $0.30 net loss per share (diluted)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}